India Vaccine Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report 2026-2030

The vaccines market encompasses products designed to prevent infectious diseases through immunization, spanning pediatric, adult, and travel health applications. Global market value in 2025 stands at approximately $66.5 billion, though estimates from other industry sources place the figure between $50 billion and $81.9 billion depending on scope and methodology. Despite some year-over-year volatility, the broader trajectory points toward sustained expansion as immunization coverage increases worldwide.

• •Market valued at approximately $66.5 billion in 2025, with projections to $75.22 billion by 2026 and beyond
• •Global shipments cover roughly 100 billion doses annually, with approximately 78% accounted for by routine immunization programs
• •India vaccine market estimated at $2.45 billion in 2024, projected to reach $5.20 billion by 2033

Robust market growth is being fueled by expanding government immunization initiatives, particularly in developing economies, alongside growing demand from aging populations requiring additional vaccine doses. Technological innovation, especially the development and commercialization of mRNA and viral vector platforms, has accelerated pipeline productivity and broadened the scope of vaccine-addressable diseases. Increasing disease burden from conditions such as pneumonia, influenza, and hepatitis, combined with rising healthcare access across emerging markets, provides a durable foundation for market expansion.

• •Government immunization programs and national health agencies driving routine vaccine uptake across Asia-Pacific and other regions
• •Aging populations in developed markets creating sustained demand for adult and senior-focused vaccines
• •mRNA and viral vector technologies expanding vaccine development pipelines for both infectious and non-infectious diseases

The market is segmented by technology into conjugate, recombinant, inactivated, live attenuated, viral vector, and mRNA vaccines, with each category serving distinct medical and logistical requirements. By product type, vaccines are classified as monovalent or multivalent formulations targeting one or multiple disease strains respectively. Disease-based segmentation includes pneumococcal, influenza, hepatitis, and MMR vaccines, among others, reflecting the varied epidemiological needs across regions.

• •Technology categories: conjugate, recombinant, inactivated, live attenuated, viral vector, and mRNA platforms
• •Disease segments span pneumococcal, flu, hepatitis, and MMR vaccines, representing some of the largest revenue contributors
• •Asia-Pacific region, led by India, is a critical growth area alongside North America and Europe as core established markets

What are the recent trends and outlook?

The market is expected to continue its upward trajectory through 2030 and beyond, with the global vaccines market projected to reach approximately $63.66 billion by 2030 under a 4.8% CAGR scenario. Emerging and re-emerging infectious disease threats, coupled with heightened pandemic preparedness awareness following recent global health events, are likely to sustain investment in vaccine research and manufacturing infrastructure. Ongoing innovation in vaccine delivery technologies and thermostable formulations promises to improve accessibility in low-resource settings, further expanding the addressable market.

• •Projected growth to approximately $63.66 billion globally by 2030 at a 4.8% CAGR
• •mRNA technology adoption expected to expand beyond COVID-19 into seasonal flu, RSV, and other infectious disease vaccines
• •Increased focus on vaccine equity and supply chain resilience shaping manufacturing and distribution strategies